Bruker Reports 2026 Revenue Growth Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
In a regulatory filing, Bruker reports that on January 12, during its scheduled presentation at the 44th Annual J.P. Morgan Healthcare Conference, Bruker provided a preliminary outlook for the full year ending December 31, 2026 of organic revenue growth of flat to up low-single digits, non-GAAP organic operating margins to expand 250 to 300 basis points, and non-GAAP earnings per share to grow in the double-digits, in each case compared to full year 2025. Consensus for 2026 revenue and EPS are $3.47B and $2.15, respectively.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on BRKR
Wall Street analysts forecast BRKR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRKR is 52.18 USD with a low forecast of 40.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
7 Buy
4 Hold
1 Sell
Moderate Buy
Current: 46.550
Low
40.00
Averages
52.18
High
60.00
Current: 46.550
Low
40.00
Averages
52.18
High
60.00
About BRKR
Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic. Its segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research. BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, and fluorescence optical microscopy instruments. BEST segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and energy physics research.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street Trades Cautiously as CPI Rises 2.7% Amid Weak Earnings Reports
- Stable Inflation Data: The Consumer Price Index (CPI) rose 2.7% year-over-year in December, matching both prior readings and economist expectations, indicating that inflationary pressures remain stable and potentially supporting future Federal Reserve rate cuts.
- Silver Price Surge: Supply concerns drove silver prices up 4.5% to $89 per ounce, marking a 22% increase since the start of the year, reflecting strong market demand and heightened risk aversion among investors.
- Major Indices Performance: By midday, the S&P 500 index remained flat at 6,970, close to the record high of 6,986 set the previous day, while the Dow Jones Industrial Average fell 0.5%, indicating cautious market sentiment.
- Stock Movements: Despite JPMorgan Chase (JPM) beating earnings estimates, its stock fell over 3%, reflecting investor concerns over weak investment banking fees, while Moderna (MRNA) surged 14% due to bullish growth forecasts in its vaccine business, highlighting a preference for biotech stocks in the current market environment.

Continue Reading
Bruker Corporation Secures $500M Multi-Year Superconductor Agreements with Global Radiology Firms
- Significant Agreement Value: Bruker's BEST division has signed two multi-year supply agreements with global radiology companies, expected to generate approximately $500 million in future revenues, with contract lengths extending up to seven years, highlighting ongoing demand for advanced MRI magnet technologies.
- Technological Support Innovation: Under the new agreements, BEST will supply superconductors engineered to meet stringent MRI magnet performance standards, primarily supporting MRI magnet production in the U.S. and the U.K., leveraging Bruker's manufacturing capabilities across Europe and the U.S. to ensure efficient delivery.
- Sustainability Drive: Bruker's advanced superconductors play a critical role in helium-free MRI magnet architectures, which not only enhance field stability and homogeneity but also reduce operating costs, aligning with the industry's increasing focus on sustainability.
- Increased Market Confidence: Bruker President Burkhard Prause noted that the expanded agreements demonstrate major OEM customers' confidence in their superconductor innovation capabilities and resilient supply chains, ensuring stability and growth in their superconducting business while further solidifying long-term partnerships with clients.

Continue Reading








